דופלקס 10160
unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 160 mg; amlodipine as besilate 10 mg - valsartan
דופלקס 10160
unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 160 mg; amlodipine as besilate 10 mg - valsartan
דופלקס 5160
unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 160 mg; amlodipine as besilate 5 mg - valsartan
דופלקס 5160
unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 160 mg; amlodipine as besilate 5 mg - valsartan
דופלקס 580
unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 80 mg; amlodipine as besilate 5 mg - valsartan
דופלקס 580
unipharm ltd, israel - amlodipine as besilate; valsartan - טבליות מצופות - valsartan 80 mg; amlodipine as besilate 5 mg - valsartan
אקספורג' 5 מג 80 מג
novartis israel ltd - amlodipine as besylate; valsartan - טבליות מצופות פילם - amlodipine as besylate 5 mg; valsartan 80 mg - amlodipine - amlodipine - treatment of essential hypertension. exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
אקספורג' 5 מג 160 מג
novartis israel ltd - amlodipine as besylate; valsartan - טבליות מצופות פילם - amlodipine as besylate 5 mg; valsartan 160 mg - amlodipine - amlodipine - treatment of essential hypertension. exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
אקספורג' 10 מג 160 מג
novartis israel ltd - amlodipine as besylate; valsartan - טבליות מצופות פילם - amlodipine as besylate 10 mg; valsartan 160 mg - amlodipine - amlodipine - treatment of essential hypertension. exforge is indicated for patients whose blood pressure is not adequately controlled on monotherapy.
ואלסרטן דקסל 40
dexcel pharma technologies ltd - valsartan - טבליות מצופות פילם - valsartan 40 mg - valsartan - valsartan - valsartan is indicated for the treatment of heart failure (nyha class ii-iv) in patients who are intolerant of angiotensin converting enzyme inhibitors. in a controlled clinical trial valsartan significantly reduced hospitalisations for heart failure. there is no evidence that valsartan provides added benefits when it is used with an adequate dose of an ace inhibitor. valsartan is indicated to improve survival following myocardial infarction in clinically stable patients with signs symptoms or radiological evidence of left ventricular failure and /or with left ventricular systolic dysfunction.